Skip to content

Market/Novel Tech

EyePoint Pharmaceuticals announce interim results from a Phase 2 EYP-1901 treatment (a tyrosine kinase inhibitor with a sustained delivery insert) for DME patients.    

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), based in Watertown, Massachusetts, have announced positive interim 16-week data for an ongoing Phase 2 “VERONA” clinical trial, evaluating “DURAVYU”… Read More »EyePoint Pharmaceuticals announce interim results from a Phase 2 EYP-1901 treatment (a tyrosine kinase inhibitor with a sustained delivery insert) for DME patients.    

Ocuphire Pharma Inc., has acquired Opus Genetics, aimed to advance treatments quickly for several ophthalmic indications.    

Ocuphire Pharma, Inc. (Nasdaq: OCUP), based in Farmington Hills, Michigan, USA announced the all-stock acquisition of Opus Genetics, Inc., a private ocular gene therapy company… Read More »Ocuphire Pharma Inc., has acquired Opus Genetics, aimed to advance treatments quickly for several ophthalmic indications.    

HuidaGene Therapeutics presents a novel AAV9 RPE-65 treatment for Leber congenital amaurosis at EURETINA Congress in Barcelona.    

HuidaGene Therapeutics, based in Shanghai, China and Clinton, New Jersey, have  reported preliminary data on a novel gene therapy treatment for RPE-65 LCA (Leber congenital… Read More »HuidaGene Therapeutics presents a novel AAV9 RPE-65 treatment for Leber congenital amaurosis at EURETINA Congress in Barcelona.